Estudo randomizado | Lenvatinibe com pembrolizumabe melhora os desfechos em comparação à quimioterapia em pacientes com câncer endometrial avançado.
21 Jan, 2022 | 15:42hLenvatinib plus Pembrolizumab for Advanced Endometrial Cancer – New England Journal of Medicine
Comentário no Twitter
In women with advanced endometrial cancer, the median progression-free survival was 7.2 months with lenvatinib plus pembrolizumab and 3.8 months with chemotherapy; the median overall survival was 18.3 months and 11.4 months, respectively. https://t.co/lzqFDnhAQn pic.twitter.com/Tm2BJZuh1D
— NEJM (@NEJM) January 19, 2022